LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
BörsenkürzelLIVN
Name des UnternehmensLivaNova PLC
IPO-datumOct 19, 2015
CEOMr. Vladimir A. Makatsaria
Anzahl der mitarbeiter2900
WertpapierartOrdinary Share
GeschäftsjahresendeOct 19
Addresse20 Eastbourne Terrace
StadtLONDON
BörseNASDAQ Global Select Consolidated
LandUnited Kingdom
PostleitzahlW2 6LG
Telefon442033250662
Websitehttps://www.livanova.com/
BörsenkürzelLIVN
IPO-datumOct 19, 2015
CEOMr. Vladimir A. Makatsaria
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten